The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.
OBJECTIVES: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs). METHOD: A total of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4208791?pdf=render |
| _version_ | 1818030770818646016 |
|---|---|
| author | Juan-Sebastian Franco Nicolás Molano-González Monica Rodríguez-Jiménez Yeny Acosta-Ampudia Rubén D Mantilla Jenny Amaya-Amaya Adriana Rojas-Villarraga Juan-Manuel Anaya |
| author_facet | Juan-Sebastian Franco Nicolás Molano-González Monica Rodríguez-Jiménez Yeny Acosta-Ampudia Rubén D Mantilla Jenny Amaya-Amaya Adriana Rojas-Villarraga Juan-Manuel Anaya |
| author_sort | Juan-Sebastian Franco |
| collection | DOAJ |
| description | OBJECTIVES: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs). METHOD: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis. RESULTS: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56-16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjögren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis. CONCLUSIONS: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients. |
| first_indexed | 2024-12-10T05:40:52Z |
| format | Article |
| id | doaj.art-0e6277a7d72b44179ab9daec57607e72 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T05:40:52Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0e6277a7d72b44179ab9daec57607e722022-12-22T02:00:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11024210.1371/journal.pone.0110242The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.Juan-Sebastian FrancoNicolás Molano-GonzálezMonica Rodríguez-JiménezYeny Acosta-AmpudiaRubén D MantillaJenny Amaya-AmayaAdriana Rojas-VillarragaJuan-Manuel AnayaOBJECTIVES: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs). METHOD: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis. RESULTS: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56-16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjögren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis. CONCLUSIONS: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.http://europepmc.org/articles/PMC4208791?pdf=render |
| spellingShingle | Juan-Sebastian Franco Nicolás Molano-González Monica Rodríguez-Jiménez Yeny Acosta-Ampudia Rubén D Mantilla Jenny Amaya-Amaya Adriana Rojas-Villarraga Juan-Manuel Anaya The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. PLoS ONE |
| title | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. |
| title_full | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. |
| title_fullStr | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. |
| title_full_unstemmed | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. |
| title_short | The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. |
| title_sort | coexistence of antiphospholipid syndrome and systemic lupus erythematosus in colombians |
| url | http://europepmc.org/articles/PMC4208791?pdf=render |
| work_keys_str_mv | AT juansebastianfranco thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT nicolasmolanogonzalez thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT monicarodriguezjimenez thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT yenyacostaampudia thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT rubendmantilla thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT jennyamayaamaya thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT adrianarojasvillarraga thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT juanmanuelanaya thecoexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT juansebastianfranco coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT nicolasmolanogonzalez coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT monicarodriguezjimenez coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT yenyacostaampudia coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT rubendmantilla coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT jennyamayaamaya coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT adrianarojasvillarraga coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians AT juanmanuelanaya coexistenceofantiphospholipidsyndromeandsystemiclupuserythematosusincolombians |